公开(公告)号：EP1259606A2

公开(公告)日：2002-11-27

申请号：EP01907820.3

申请日：2001-02-15

申请人： Aventis Pharma S.A. ,  INSTITUT NATIONAL DE LA SANTE ET DE LARECHERCHE MEDICALE (INSERM)

发明人： KOUTNIKOVA, Hana ,  BRICE, Alexis ,  FOURNIER, Alain ,  PRADIER, Laurent ,  PRADES, Catherine ,  ARNOULD-REGUIGNE, Isabelle ,  ROSIER-MONTUS, Marie-Françoise ,  CORTI, Olga

IPC分类号： C12N15/12 ,  C12N5/10 ,  C07K14/47 ,  C07K16/18 ,  G01N33/50 ,  A61K38/17

CPC分类号： C07K14/47 ,  A01K2217/05 ,  A61K38/00 ,  A61K48/00 ,  C07K2319/00

摘要： The invention concerns novel compounds and their uses, in particular pharmaceutical, diagnostic or as pharmacological targets. More particularly, the invention concerns a novel protein, called PAP1, and novel peptides and compounds capable of modulating at least partially parkin gene activity.

公开(公告)号：EP1200471A1

公开(公告)日：2002-05-02

申请号：EP00949647.2

申请日：2000-07-06

申请人： Aventis Pharma S.A.

发明人： DUMAS, Jacques ,  REY, Lucien ,  SARUBBI, Edoardo

IPC分类号： C07K14/535 ,  C07K1/20

CPC分类号： C07K14/535

摘要： The invention concerns a method for purifying G-CSF from a biological sample comprising steps which consist in: a) reducing the volume of the biological sample containing the G-CSF by hydrophobic interaction chromatography to obtain a concentrated, desalted and enriched fraction; b) passing the concentrated fraction over hydroxyapatite in conditions whereby the G-CSF is slightly bound to obtain a concentrated, desalted and enriched fraction containing the G-CSF; and c) collecting the G-CSF.

公开(公告)号：EP1144651A1

公开(公告)日：2001-10-17

申请号：EP00900608.1

申请日：2000-01-19

申请人： Aventis Pharma S.A.

发明人： DESANLIS, Francine ,  FOURNIER, Alain ,  MAURY, Isabelle ,  ZHOU-LIU, Qing

IPC分类号： C12N15/54 ,  C12N9/12 ,  C12N15/81 ,  C12N1/19 ,  C07K16/40 ,  G01N33/68 ,  A61K39/395

CPC分类号： C12N9/1205 ,  A61K38/00

摘要： The invention concerns the field of biology and the regulation of the cell cycle. More particularly, the invention concerns polypeptides derived from the human JNK3 protein, their variants, the corresponding nucleotide sequences, and their uses.

公开(公告)号：EP1053341A1

公开(公告)日：2000-11-22

申请号：EP99900923.6

申请日：1999-01-14

申请人： Aventis Pharma S.A.

发明人： KIEFER, Hélène ,  MALLET, Jacques ,  MILLECAMPS, Stéphanie

IPC分类号： C12N15/86 ,  C12N5/10 ,  C12N5/06 ,  A61K48/00

CPC分类号： A61K48/00 ,  C12N7/00 ,  C12N15/86 ,  C12N2710/10043 ,  C12N2799/022 ,  C12N2830/005 ,  C12N2830/008 ,  C12N2830/15 ,  C12N2830/32

摘要： The invention concerns novel methods and constructs for controlling nucleic acid expression, in particular methods and constructs using NRSE sequences for obtaining a targeted expression of transgenes in the nerve cells in vivo or ex vivo. The invention is particularly adapted for in vivo gene transfer applications, for instance for therapeutic or scientific approach.

公开(公告)号：EP3170005B1

公开(公告)日：2019-04-10

申请号：EP15738625.1

申请日：2015-07-16

申请人： SANOFI

发明人： CHIRON -BLONDEL, Marielle ,  LAMBRECHTS, Diether ,  MAGHERINI, Emmanuelle ,  THUILLIER, Vincent

IPC分类号： G01N33/574

公开(公告)号：EP2938358A2

公开(公告)日：2015-11-04

申请号：EP13821489.5

申请日：2013-12-26

申请人： SANOFI

发明人： BAUDAT, Yves ,  BLANCHE, Francis ,  CAMERON, Béatrice ,  DABDOUBI, Tarik ,  LEFEBVRE, Anne-Marie ,  MATHIEU, Magali ,  MERINO-TRIGO, Ana ,  NUNES, Manoel

IPC分类号： A61K39/395 ,  A61P35/00 ,  C12Q1/68 ,  C07K16/28 ,  A61K47/48

CPC分类号： C07K16/2896 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6851 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6863 ,  A61K2039/505 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3069 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156 ,  G01N33/574

摘要： Antibodies are provided which specifically bind human and Macaca fascicularis lysosomal-associated membrane protein 1 (LAMP1) proteins and immunoconjugates comprising said antibodies conjugated or linked to a growth inhibitory agent. Pharmaceutical compositions comprising antibodies or immunoconjugates of the invention and use of the antibodies or immunoconjugates for the treatment of cancer are also provided, as well as LAMP1 antibodies, isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies and the use of said antibody as a diagnostic tool. The application further provides for the detection of LAMP1 gene amplification or gain in cancer cells leading to the determination if patients with cancer are likely to respond to anti-LAMP1 therapy. Anti-LAMP1 therapeutic agent for use for treating cancer in a patient harboring LAMP1 gene copy number gain in cancer cells is further provided.

摘要翻译： 提供了特异性结合人和食蟹猕猴（Macaca fascicularis）溶酶体相关膜蛋白1（LAMP1）蛋白的抗体和包含与生长抑制剂缀合或连接的所述抗体的免疫缀合物。 还提供了包含本发明的抗体或免疫缀合物的药物组合物以及抗体或免疫缀合物用于治疗癌症的用途，以及LAMP1抗体，包含编码所述抗体的序列的分离的核酸，载体和宿主细胞，以及所述 抗体作为诊断工具。 本申请还提供了检测癌细胞中的LAMP1基因扩增或增加，从而导致确定癌症患者是否可能对抗LAMP1疗法有反应。 因此，提出了选择癌症患者的体外方法，其包括在患有癌细胞的癌症患者的生物样品中确定所述患者携带LAMP1基因拷贝数增益; 并根据LAMP1基因拷贝数增益的存在选择患者。 进一步提供了用于治疗患有癌症细胞中LAMP1基因拷贝数增加的患者的癌症的抗LAMP1治疗剂。

公开(公告)号：EP2701724A1

公开(公告)日：2014-03-05

申请号：EP12717129.6

申请日：2012-04-25

申请人： SANOFI

发明人： CASTAN, Rémi

IPC分类号： A61K38/17 ,  A61K31/4745 ,  A61K31/505 ,  A61K31/519 ,  A61P35/00

CPC分类号： A61K38/17 ,  A61K9/0019 ,  A61K31/4745 ,  A61K31/513 ,  A61K31/519 ,  A61K38/00 ,  A61K38/178 ,  A61K2300/00

摘要： Pharmaceutical composition comprising aflibercept, folinic acid, 5-fluorouracil (5-FU) and irinocetan (FOLFIRI) useful in the treatment of Colorectal cancer (CRC).

摘要翻译： 药物组合物，其包含可用于治疗结肠直肠癌（CRC）的替氟西泮，亚叶酸，5-氟尿嘧啶（5-FU）和伊立替康（FOLFIRI）。

公开(公告)号：EP1745123B1

公开(公告)日：2012-07-11

申请号：EP05763706.8

申请日：2005-05-02

申请人： Aventis Pharma S.A.

发明人： POMPON, Denis ,  DUMAS, Bruno ,  SPAGNOLI, Roberto

IPC分类号： C12N1/18 ,  A61K51/04 ,  C07B59/00 ,  C12P33/00

CPC分类号： A61K51/0493 ,  C07B2200/05 ,  C12P33/00

摘要： The invention concerns the production of cholesterol in organisms of the Fungi kingdom. More particularly, the invention concerns genetically modified Fungus independently producing cholesterol from a simple carbon source. The invention also concerns the use of the inventive Fungus for producing non-marked and marked cholesterol.

公开(公告)号：EP1594964B1

公开(公告)日：2012-04-11

申请号：EP04709264.8

申请日：2004-02-09

申请人： Aventis Pharma S.A. ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  Centre National de la Recherche Scientifique (CNRS)

发明人： JOCKERS, Ralf ,  COUTURIER, Cyril ,  UHLMANN, Eugen

IPC分类号： C12N15/113

CPC分类号： C12N15/1138 ,  A61K38/00 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/346 ,  C12N2310/351 ,  C12N2310/53 ,  G01N2333/715 ,  C12N2310/3521

摘要： The invention relates to oligonucleotides which inhibit the expression of the OB-RGRP protein and use thereof for the prevention and/or treatment of diseases related to leptin. The invention further relates to a method for detection of compounds modifying the interaction between the proteins of the OB-RGRP family and the leptin receptor. Said detection can be achieved by means of the energy transfer between the fusion proteins comprising said proteins and proteins which are donors and acceptors of energy.

公开(公告)号：EP1025121B1

公开(公告)日：2011-08-24

申请号：EP98951547.3

申请日：1998-10-23

申请人： Aventis Pharma S.A.

发明人： CZECH, Christian ,  MERCKEN, Luc ,  PRADIER, Laurent ,  REBOUL-BECQUART, Soline

IPC分类号： C07K14/47 ,  C12N15/12 ,  C12N5/10 ,  C12N15/86 ,  C07K16/18

CPC分类号： G01N33/502 ,  A61K38/00 ,  A61K48/00 ,  C07K14/4711 ,  C07K2319/02 ,  C12N2799/021 ,  G01N33/5008 ,  G01N33/542 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2500/02

摘要： The invention concerns novel peptide and nucleotide sequences, and their pharmaceutical use. More particularly, the invention concerns novel polypeptides capable of inhibiting at least partially the interaction between presenilin 1 or presenilin 2 and the β-amyloid peptide precursor and/or the β-amyloid peptide. The invention also concerns the preparation of in vitro tests for detecting molecules and in particular molecules capable of inhibiting said interaction.